View as Webpage

Products

Support

Resources

Insights

About Us

🌟Frontiers in immunotherapy🌟

LILRB + HLA-G, A New Ground-breaking Immunotherapy Combination

As the competition in cutting-edge drug research and development intensifies, selecting potential novel targets and forging a unique, visionary path can help innovators stand out. Studies have revealed that the HLA-G/LILRBs pathway has a broader impact than CTLA-4 and PD-1/PD-L1 regulated immune cells. The interaction of HLA-G with LILRB1 has been proven to inhibit the function of NK cells, dendritic cells, monocytes/macrophages, T cells, and B cells, therefore aiding tumor escape. Therefore, LILRB and HLA-G may become the next hot immunotherapy targets.

Read more

Based on unique biotin labeling technology, ACROBiosystems has released a high-quality HLA-G tetramer protein (Cat. No. HLG-H52E9). These tetramer proteins have been shown to amplify cell signals, stronger activities, and improved inhibitory effects on LILRB and HLA-G pathways.

Furthermore, ACROBiosystems has also released a series of high-quality LILRBs proteins.

All those products can be used for immunosuppression research of LILRBs and HLA-G pathways.

Assay Data

Homogenous aggregate structure and purity by MALS verification

The purity of Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein (Cat. No. HLG-H52E9) is more than 85% and the molecular weight of this protein is around 228-278 kDa verified by SEC-MALS.

Learn more data and download the free protocols

You may be interested in:

More BsAb target proteins

More ADC target proteins

More multi-pass Transmembrane Proteins

WE ARE HIRING!

We are also available at Fisher and VWR!

To receive the latest industry news and updates from ACROBiosystems,

visit our website & follow us on our social media!

Visit our Website
Facebook  LinkedIn  Twitter  YouTube